Base Editing Corrects Untreatable Cystic Fibrosis Mutation in Human Cells
A CRISPR-based adenine base editor restores CFTR function in airway cells and intestinal organoids from CF patients with a previously undruggable mutation.
Summary
Researchers developed a gene-editing approach to fix a cystic fibrosis mutation called 1717-1G>A, which currently has no approved drug treatment. Using a refined CRISPR tool called adenine base editing, they corrected the faulty DNA letter in human airway cells and intestinal organoids taken from CF patients. The editing restored normal protein function, measured by two established lab tests. This approach works by precisely swapping one DNA base for another without cutting the DNA strand, reducing the risk of unintended changes. The results suggest this strategy could one day offer a permanent genetic fix for people with this specific CF mutation, who are currently left out of the benefits of newer CF modulator drugs.
Detailed Summary
Cystic fibrosis affects tens of thousands of people worldwide, but not all mutations respond to the same treatments. The 1717-1G>A mutation disrupts a critical splice site in the CFTR gene, causing the cell to produce a malformed, nonfunctional protein. Unlike many other CF mutations now addressable by modulator drugs like Trikafta, this splicing mutation has no approved pharmacological therapy, leaving affected patients with limited options.
Researchers from the University of Trento, KU Leuven, and collaborating institutions developed an adenine base editing strategy using a tool called ABE9 paired with a PAM-relaxed Cas9 variant known as SpRY. This combination allows precise A-to-G correction at the mutation site without introducing double-strand DNA breaks, which reduces the risk of large deletions or chromosomal rearrangements associated with traditional CRISPR cutting.
In HEK293 cell models, the team achieved up to 30% editing efficiency with minimal off-target bystander edits. Critically, they then validated the approach in clinically relevant models: airway epithelial cells grown at an air-liquid interface and intestinal organoids derived directly from CF patients carrying the 1717-1G>A mutation. Functional restoration of CFTR channel activity was confirmed using short-circuit current measurements and the forskolin-induced swelling assay, both gold-standard readouts of CFTR function.
The delivery method — electroporation of base editor mRNA and guide RNA — avoids viral vectors and their associated immunogenicity concerns, which is a practical advantage for potential therapeutic translation.
While these findings are promising, the work remains preclinical. Editing efficiency of 30% may need to be higher for meaningful clinical benefit, and in vivo delivery to lung tissue presents substantial additional challenges. The summary is based on the abstract only, and full methodology details were not available for review.
Key Findings
- ABE9-SpRY base editing corrected the 1717-1G>A CFTR mutation with up to 30% efficiency in cell models.
- CFTR channel function was restored in patient-derived airway epithelial cells and intestinal organoids.
- Minimal bystander edits were observed, suggesting high precision of the editing approach.
- mRNA and sgRNA delivery via electroporation avoids viral vectors, reducing immunogenicity risk.
- This is the first reported functional correction strategy for this previously undruggable CF mutation.
Methodology
The study used HEK293 cell models, patient-derived airway epithelial cells in air-liquid interface culture, and intestinal organoids from CF patients carrying the 1717-1G>A mutation. CFTR function was assessed via short-circuit current measurements and forskolin-induced swelling assays. Base editor components were delivered by electroporation of mRNA and sgRNA.
Study Limitations
This summary is based on the abstract only, as the full paper was not accessible; detailed methodology and safety data could not be reviewed. Editing efficiency of ~30% may be insufficient for robust clinical benefit, and in vivo delivery to lung epithelium remains a major translational hurdle. Long-term durability and off-target effects across the full genome were not assessable from available information.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.